Apogee Therapeutics, Correlations
APGE Stock | 40.14 0.25 0.63% |
The current 90-days correlation between Apogee Therapeutics, and National Beverage Corp is 0.31 (i.e., Weak diversification). The correlation of Apogee Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Apogee Therapeutics, Correlation With Market
Modest diversification
The correlation between Apogee Therapeutics, Common and DJI is 0.26 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Apogee Therapeutics, Common and DJI in the same portfolio, assuming nothing else is changed.
Apogee |
Moving together with Apogee Stock
0.76 | ELVN | Enliven Therapeutics | PairCorr |
0.65 | SCLX | Scilex Holding | PairCorr |
0.63 | ASMB | Assembly Biosciences Downward Rally | PairCorr |
0.71 | CDIO | Cardio Diagnostics | PairCorr |
0.84 | CRNX | Crinetics Pharmaceuticals | PairCorr |
0.63 | MRK | Merck Company | PairCorr |
Moving against Apogee Stock
0.79 | WM | Waste Management | PairCorr |
0.69 | LUCD | Lucid Diagnostics | PairCorr |
0.69 | GE | GE Aerospace | PairCorr |
0.55 | PLX | Protalix Biotherapeutics | PairCorr |
0.46 | PG | Procter Gamble | PairCorr |
0.38 | ABUS | Arbutus Biopharma Corp | PairCorr |
0.34 | WMT | Walmart | PairCorr |
0.84 | CSCO | Cisco Systems Aggressive Push | PairCorr |
0.68 | JNJ | Johnson Johnson | PairCorr |
0.68 | DD | Dupont De Nemours | PairCorr |
0.67 | T | ATT Inc Aggressive Push | PairCorr |
0.67 | IBM | International Business | PairCorr |
0.66 | MMM | 3M Company | PairCorr |
0.58 | CVX | Chevron Corp | PairCorr |
0.51 | INTC | Intel | PairCorr |
0.45 | JPM | JPMorgan Chase Sell-off Trend | PairCorr |
0.35 | XOM | Exxon Mobil Corp Earnings Call This Week | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Apogee Stock performing well and Apogee Therapeutics, Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Apogee Therapeutics,'s multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
FMX | 1.23 | 0.19 | 0.13 | 0.66 | 1.26 | 2.99 | 7.97 | |||
CF | 1.65 | (0.12) | 0.00 | (0.15) | 0.00 | 2.51 | 15.08 | |||
BUD | 0.99 | 0.32 | 0.20 | 1.15 | 1.14 | 2.29 | 9.20 | |||
ECL | 0.85 | 0.09 | 0.09 | 0.13 | 0.95 | 1.63 | 8.71 | |||
UAN | 1.07 | 0.07 | 0.05 | 0.08 | 1.31 | 1.97 | 9.48 | |||
FIZZ | 1.15 | (0.19) | 0.00 | 1.96 | 0.00 | 2.24 | 7.80 | |||
ALB-PA | 1.62 | (0.15) | 0.00 | (0.19) | 0.00 | 3.60 | 11.25 | |||
KO | 0.90 | 0.13 | 0.13 | (0.39) | 0.89 | 1.87 | 7.65 |
Apogee Therapeutics, Corporate Management
Carl MD | Chief Officer | Profile | |
Noel Kurdi | Vice Relations | Profile | |
Drew Badger | Senior Toxicology | Profile | |
Monica Forbes | Senior Finance | Profile | |
Matthew JD | General Counsel | Profile | |
Jane Henderson | Chief Officer | Profile | |
Dan Mulreany | Senior Strategy | Profile |